Drug Type Small molecule drug |
Synonyms N-[4-(1,3-thiazol-2-ylaminosulfonyl)phenyl]-3-{(E)-5-[(2-methoxyphenyl)methylene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl} |
Target |
Action inhibitors |
Mechanism FURIN inhibitors(furin, paired basic amino acid cleaving enzyme inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H20N4O5S4 |
InChIKeyJBJLCKKRGZERTK-UHFFFAOYSA-N |
CAS Registry299952-98-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | Slovenia | 19 Feb 2025 |